Snowden JA, Sánchez-ortega I, Corbacioglu S, Basak GW, Chabannon C, Camara R, et al. Indications for haematopoietic cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2022. 2022;(May).

Cieri N, Maurer K, Wu CJ. 60 years young: The evolving role of allogeneic hematopoietic stem cell transplantation in cancer immunotherapy. Cancer Res. 2021;81:4373–84.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Perez-Simón JA, Martino R, Parody R, Cabrero M, Lopez-Corral L, Valcarcel D, et al. The combination of sirolimus plus tacrolimus improves outcome after reduced-intensity conditioning, unrelated donor hematopoietic stem cell transplantation compared with cyclosporine plus mycofenolate. Haematologica. 2013;98:526–32.

Article  PubMed  PubMed Central  Google Scholar 

Bailén R, Kwon M, Pascual-Cascón MJ, Ferrà C, Sanz J, Gallardo-Morillo A, et al. Post-transplant cyclophosphamide for GVHD prophylaxis compared to ATG-based prophylaxis in unrelated donor transplantation. Ann Hematol. 2021;100:541–53. http://link.springer.com/10.1007/s00277-020-04317-7.

Mehta RohteshS, Saliba RimaM, Chen Julianne, Rondon Gabriela, Hammerstrom AimeeE, Alousi Amin, et al. Post-transplantation cyclophosphamide versus conventional graft-versus-host disease prophylaxis in mismatched unrelated donor haematopoietic cell transplantation. Br J Haematol. 2016;173:444–55.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Maurer K, Ho VT, Inyang E, Cutler CS, Koreth J, Shapiro RM, et al. Posttransplant cyclophosphamide vs tacrolimus-based GVHD prophylaxis: lower incidence of relapse and chronic GVHD. Blood Adv. 2023;7:3903–15. https://doi.org/10.1182/bloodadvances.2023009791.

Article  CAS  PubMed  PubMed Central  Google Scholar 

McCurdy SR, Luznik L. Relapse after allogeneic transplantation with post-transplant cyclophosphamide: Shattering myths and evolving insight. Blood Rev. 2023:101093. https://doi.org/10.1016/j.blre.2023.101093

Mussetti A, Kanate AS, Wang T, He M, Hamadani M, Finel H, et al. Haploidentical versus matched unrelated donor transplants using post-transplantation cyclophosphamide for lymphomas. Transpl Cell Ther. 2023;29:184.e1–184.e9.

Article  CAS  Google Scholar 

Bolaños-Meade J, Hamadani M, Wu J, Al Malki MM, Martens MJ, Runaas L, et al. Post-transplantation cyclophosphamide-based graft-versus-host disease prophylaxis. N. Engl J Med. 2023;388:2338–48.

Article  PubMed  PubMed Central  Google Scholar 

García-Cadenas I, Esquirol A, Bosch-Vilaseca A, Awol R, Novelli S, Saavedra S, et al. Patterns of infection and infectious-related mortality in patients receiving post-transplant high dose cyclophosphamide as graft-versus-host-disease prophylaxis: impact of HLA donor matching. Bone Marrow Transpl. 2021;56:818–27. https://doi.org/10.1038/s41409-020-01092-x.

Article  CAS  Google Scholar 

Ruggeri A, Labopin M, Ciceri F, Mohty M, Nagler A. Definition of GvHD-free, relapse-free survival for registry-based studies: An ALWP-EBMT analysis on patients with AML in remission. Bone Marrow Transpl. 2016;51:610–1.

Article  CAS  Google Scholar 

Jagasia MH, Greinix HT, Arora M, Williams KM, Cheng G, Kerr H, et al. National institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease. Biol Blood Marrow Transpl. 2015;21:389–401.

Article  Google Scholar 

Copelan E, Casper JT, Carter SL, van Burik JAH, Hurd D, Mendizabal AM, et al. A scheme for defining cause of death and its application in the T cell depletion trial. Biol Blood Marrow Transpl. 2007;13:1469–76.

Article  Google Scholar 

Sathish N, Wu CA. Let’s flip: an approach to understand median follow-up by the reverse Kaplan-Meier estimator from a statistical programmer’s perspective. PharmaSUG. 2019;1:5.

Google Scholar 

Austin PC, Stuart EA. Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies. Stat Med. 2015;34:3661–79.

Article  PubMed  PubMed Central  Google Scholar 

Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivar Behav Res. 2011;46:399–424.

Article  Google Scholar 

Cutler C, Logan B, Nakamura R, Johnston L, Choi S, Porter D, et al. Tacrolimus/sirolimus vs tacrolimus/methotrexate as GVHD prophylaxis after matched, related donor allogeneic HCT. Blood. 2014;124:1372–7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ho VT, Aldridge J, Kim HT, Cutler C, Koreth J, Antin JH, et al. Comparison of Tacrolimus and Sirolimus (Tac/Sir) versus Tacrolimus, Sirolimus, and mini-methotrexate (Tac/Sir/MTX) as acute graft-versus-host disease prophylaxis after reduced-intensity conditioning allogeneic peripheral blood stem cell transplantation. Biol Blood Marrow Transpl. 2009;15:844–50.

Article  CAS  Google Scholar 

Khimani F, Kim J, Chen L, Dean E, Rizk V, Betts B, et al. Predictors of overall survival among patients treated with sirolimus/tacrolimus vs methotrexate/tacrolimus for GvHD prevention. Bone Marrow Transpl. 2017;52:1003–9. https://doi.org/10.1038/bmt.2017.63.

Article  CAS  Google Scholar 

Kanakry CG, O’Donnell PV, Furlong T, De Lima MJ, Wei W, Medeot M, et al. Multi-institutional study of post-transplantation cyclophosphamide as single-agent graft-versus-host disease prophylaxis after allogeneic bone marrow transplantation using myeloablative busulfan and fludarabine conditioning. J Clin Oncol. 2014;32:3497–505.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Broers AEC, de Jong CN, Bakunina K, Hazenberg MD, van Marwijk Kooy M, de Groot MR, et al. Posttransplant cyclophosphamide for prevention of graft-versus-host disease: results of the prospective randomized HOVON-96 trial. Blood Adv. 2022;6:3378–85.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mehta RS, Saliba RM, Rondon G, Al-Atrash G, Bashir Q, Hosing CM, et al. Post-transplantation cyclophosphamide versus tacrolimus and methotrexate graft-versus-host disease prophylaxis for HLA-matched donor transplantation. Transpl Cell Ther. 2022;28:695.e1–695.e10. https://doi.org/10.1016/j.jtct.2022.07.021.

Article  CAS  Google Scholar 

Holtan SG, Hamadani M, WU J, AL Malki MM, Runaas L, Elmariah H, et al. Post-transplant cyclophosphamide, tacrolimus, and mycophenolate mofetil as the new standard for graft-versus-host disease (GVHD) prophylaxis in reduced intensity conditioning: results from phase III BMT CTN 1703. Blood. 2022;140:LBA-4–LBA-4. https://doi.org/10.1182/blood-2022-171463.

Article  Google Scholar 

García-Cadenas I, Redondo S, Esquirol A, Portos JM, Novelli S, Saavedra S, et al. Successful outcome in patients with myelofibrosis undergoing allogeneic donor hematopoietic cell transplantation using reduced doses of post-transplantation cyclophosphamide: challenges and review of the literature. Transpl Cell Ther. 2023;29:1–6.

Article  Google Scholar 

McAdams MJ, Hyder M, Dimitrova D, Sadler JL, McKeown C, Steinberg SM, et al. Phase I/II study of reduced dosing of post-transplantation cyclophosphamide (PTCy) after HLA-haploidentical bone marrow transplantation. Blood. 2021;138:101–101.

Article  Google Scholar 

García-Cadenas I, Awol R, Esquirol A, Saavedra S, Bosch-Vilaseca A, Novelli S, et al. Incorporating posttransplant cyclophosphamide-based prophylaxis as standard-of-care outside the haploidentical setting: challenges and review of the literature. Bone Marrow Transpl. 2020;55:1041–9. https://doi.org/10.1038/s41409-019-0771-2.

Article  CAS  Google Scholar 

Oltolini C, Greco R, Galli L, Clerici D, Lorentino F, Xue E, et al. Infections after allogenic transplant with post-transplant cyclophosphamide: impact of donor HLA matching. Biol Blood Marrow Transpl. 2020;26:1179–88.

Article  Google Scholar 

Mehta RS, Saliba RM, Ghanem S, Alousi AM, Rondon G, Anderlini P, et al. Haploidentical versus matched unrelated versus matched sibling donor hematopoietic cell transplantation with post-transplantation cyclophosphamide. Transpl Cell Ther. 2022;28:395.e1–395.e11. https://doi.org/10.1016/j.jtct.2022.04.020.

Article  CAS  Google Scholar 

Mikulska M, Bartalucci C, Raiola AM, Oltolini C. Does PTCY increase the risk of infections? Blood Rev. 2023:101092. https://doi.org/10.1016/j.blre.2023.101092.

McCurdy SR, Luznik L. Immune reconstitution after T-cell replete HLA-haploidentical transplantation. Semin Hematol. 2019;56:221–6.

Aldiwani M, Tharakan T, Al-Hassani A, Gibbons N, Pavlu J, Hrouda D. BK Virus Associated Haemorrhagic Cystitis. A systematic review of current prevention and treatment strategies. Int J Surg. 2019;63:34–42. https://doi.org/10.1016/j.ijsu.2019.01.019.

Article  CAS  PubMed  Google Scholar 

Salas MQ, Prem S, Atenafu EG, Datt Law A, Lam W, Al-Shaibani Z, et al. Dual T-cell depletion with ATG and PTCy for peripheral blood reduced intensity conditioning allo-HSCT results in very low rates of GVHD. Bone Marrow Transpl. 2020;55:1773–83. https://doi.org/10.1038/s41409-020-0813-9.

Article  CAS  Google Scholar 

Mohyuddin GR, Roller J, Shune L, Lin T, Dias A, Ganguly S, et al. Epstein-Barr viremia and post-transplant lymphoproliferative disorders in patients undergoing haploidentical stem cell transplantation with post-transplant cyclophosphamide. Hematol Oncol Stem Cell Ther. 2019;12:171–3. https://doi.org/10.1016/j.hemonc.2018.11.002.

Article  PubMed  Google Scholar 

Imus PH, Tsai HL, DeZern AE, Jerde K, Swinnen LJ, Bolaños-Meade J, et al. Thrombotic Microangiopathy after Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis. Biol Blood Marrow Transpl. 2020;26:2306–10.

Article  CAS  Google Scholar 

Holtan SG, DeFor TE, Lazaryan A, Bejanyan N, Arora M, Brunstein CG, et al. Composite end point of graft-versus-host disease-free, relapse-free survival after allogeneic hematopoietic cell transplantation. Blood. 2015;125:1333–8.